New spin-outs launched to draw on Oxford University research

OxStem, an Oxford University spin-out developing regenerative medicine-based therapies, is launching two subsidiary companies to develop regenerative treatments for diabetes and chronic inflammation and wound healing.

Named OxStem Beta and OxStem Immuno, they are the fifth and sixth subsidiaries set up since OxStem was initially spun out from the university in May 2016. The other four have a focus on cancer, neurological diseases, ocular diseases and heart disease.

OxStem Beta will develop therapeutics which stimulate regeneration of insulin-producing beta cells using small molecules to treat types I and II diabetes.